Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination 2
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality and submitted it to the Institute.
The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on Thursday 4 September 2014.
This page was last updated: 20 August 2014